Pathstone Holdings
SRPT icon

Pathstone Holdings’s Sarepta Therapeutics SRPT Stock Holding History

Pathstone Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,181
Closed -$586K – 2337
2025
Q1 		$586K Buy
9,181
+279
+3% +$29.4K ﹤0.01% 1643
2024
Q4 		$1.08M Buy
8,902
+1,785
+25% +$219K ﹤0.01% 1329
2024
Q3 		$889K Sell
7,117
-160
-2% -$22.1K ﹤0.01% 1437
2024
Q2 		$1.15M Buy
7,277
+226
+3% +$29K 0.01% 1247
2024
Q1 		$913K Buy
7,051
+2,441
+53% +$299K ﹤0.01% 1331
2023
Q4 		$445K Buy
+4,610
New +$442K ﹤0.01% 1583

Other funds holding SRPT

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return